Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

268
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
268
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

257
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
257
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Risk Score to Risk Phenotype: Cardiac MRI and Machine Learning in Hypertrophic Cardiomyopathy.

Radiology. Cardiothoracic imaging·2026
Same author

Microstructural disease and hypoperfusion in dilated cardiomyopathy underpin midwall septal fibrosis.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance·2026
Same author

ESPriT1: the effectiveness of laparoscopic treatment of isolated superficial peritoneal endometriosis for managing chronic pelvic pain in women: a randomised controlled feasibility trial.

Reproduction & fertility·2026
Same author

Comparative Evaluation of Perceived Cognitive Load Across Two Academic Cycles in an Undergraduate Obstetrics and Gynecology Course With an Evolving Clinical Tutor Role: Comparative Student Feedback Analysis.

Cureus·2026
Same author

Incidental findings and duty-of-care protocols in cardiovascular magnetic resonance among older adults: a prospective population-based study from MyoFit46.

The lancet. Healthy longevity·2026
Same author

Building a foundation to promote Women's health research in Dubai. Study protocol for a project to investigate the feasibility of establishing a dedicated Women's health biobank.

Frontiers in global women's health·2026

Related Experiment Video

Updated: Jun 27, 2025

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.6K

Metformin for endometrial hyperplasia.

Hunain Shiwani1, Naomi S Clement2, Jane P Daniels3

  • 1Faculty of Population Health Sciences, University College London, London, UK.

The Cochrane Database of Systematic Reviews
|May 2, 2024
PubMed
Summary
This summary is machine-generated.

Metformin shows potential for treating endometrial hyperplasia, but evidence is limited. More high-quality trials are needed to confirm its effectiveness and safety compared to existing treatments for this precancerous condition.

More Related Videos

Noninvasive Monitoring of Lesion Size in a Heterologous Mouse Model of Endometriosis
08:16

Noninvasive Monitoring of Lesion Size in a Heterologous Mouse Model of Endometriosis

Published on: February 26, 2019

8.2K
Establishment of an Experimental Mouse Model of Endometrioma to Study its Related Infertility
08:13

Establishment of an Experimental Mouse Model of Endometrioma to Study its Related Infertility

Published on: April 5, 2024

815

Related Experiment Videos

Last Updated: Jun 27, 2025

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.6K
Noninvasive Monitoring of Lesion Size in a Heterologous Mouse Model of Endometriosis
08:16

Noninvasive Monitoring of Lesion Size in a Heterologous Mouse Model of Endometriosis

Published on: February 26, 2019

8.2K
Establishment of an Experimental Mouse Model of Endometrioma to Study its Related Infertility
08:13

Establishment of an Experimental Mouse Model of Endometrioma to Study its Related Infertility

Published on: April 5, 2024

815

Area of Science:

  • Gynecology
  • Oncology
  • Pharmacology

Background:

  • Endometrial cancer rates are rising, partly due to obesity.
  • Endometrial hyperplasia is a precancerous condition that can progress to cancer.
  • Current treatments for endometrial hyperplasia have significant adverse effects or limitations.

Approach:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs) and cross-over trials.
  • Searched multiple databases including Cochrane, MEDLINE, PubMed, and Embase.
  • Included studies comparing metformin (alone or combined) against placebo, no treatment, or standard therapies for endometrial hyperplasia.

Key Points:

  • Metformin plus megestrol may improve hyperplasia regression compared to megestrol alone (low-certainty evidence).
  • Evidence is uncertain regarding metformin's effectiveness versus megestrol or levonorgestrel intrauterine systems.
  • High risk of bias in blinding and outcome assessment was noted in many included studies.

Conclusions:

  • Insufficient evidence exists to support or refute metformin's use for endometrial hyperplasia.
  • Robust, well-powered RCTs with long-term data are required to clarify metformin's role.
  • Further research is essential to establish optimal treatment strategies for endometrial hyperplasia.